Company intelligence / Profile preview

DNano MetaBio

Hangzhou, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

DNano MetaBio is an early-stage biotech founded in 2022 developing DNA/RNA-based nanocarriers for targeted delivery of small molecules, mRNA vaccines, protein vaccines, and siRNA, with all known programs currently in preclinical development focused mainly on neoplasms (cancer) and related severe diseases.

Therapeutic areas: OncologyMetabolic Disorders
Modalities: Small moleculemRNA vaccineVaccineProteinSmall interfering RNAsiRNANanoparticleNanoparticle (nucleic acid nanocarrier)
Industry: Biotech

Partnerships

Participation in Novo Nordisk / ATLATL joint program EntreStar as a winner, indicating collaboration/exposure but no specific formal development partnership disclosed.

Beyond the preview

Go deeper on DNano MetaBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNano MetaBio.

Explore the full profile